Determine the Mycobacterium tuberculosis resistance and sensitivity pattern in the Dhaka South City Corporation (DSCC) area using 10-color GeneXpert assay with XDR cartridge

 Bangladesh is one of the high-burden countries of drug-resistant tuberculosis (TB) in the world. Only early diagnosis and proper selection of anti-tubercular treatment (ATT) combat the crisis. The study aims to determine M. tuberculosis resistance and sensitivity pattern in the Dhaka South City Corporation (DSCC) Area.

A cross-sectional observational study designed to determine the M. tuberculosis résistance and sensitivity pattern with Xpert XDR cartridge assay at RTRL, Shamoli. The potential drug resistance TB patients go for Xpert XDR assay, a molecular diagnostic test to determine the M. tuberculosis resistance and sensitivity pattern.

 

One hundred nine potential drug resistance TB patients Xpert XDR assay was done. The result shows that working-class male of productive age suffers more. DR-TB presumptive age group among people of 35-44 years of age suffer more for DR-TB. It was 24 (22%), and followed by people 25-43 years of age. They were 20 (18.3%). The elderly people also suffered more and were above 65 years of age. They were 14 (12.8%).

Age Group
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	5-14	2	1.8	1.9	1.9
	15-24	21	19.3	20.0	21.9
	25-34	20	18.3	19.0	41.0
	35-44	24	22.0	22.9	63.8
	45-54	13	11.9	12.4	76.2
	55-64	11	10.1	10.5	86.7
	>65	14	12.8	13.3	100.0
	Total	105	96.3	100.0
Missing	System	4	3.7
Total		109	100.0

 

DR-TB presumptive resistance and sensitivity pattern. Among 109 XDR assays, INH resistance was 25 (22.9%), Fluoroquinolone resistance was 3 (2.6%), and All MDR-TB were sensitive in 64 (58.7%). M. tuberculosis was not detected among 10 (9.2%).

Resistance and Sensitivity
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	INH	25	22.9	23.6	23.6
	RIF	4	3.7	3.8	27.4
	FLQ	3	2.8	2.8	30.2
	Sanative	64	58.7	60.4	90.6
	No Mtb	10	9.2	9.4	100.0
	Total	106	97.2	100.0
Missing	System	3	2.8
Total		109	100.0

Early diagnosis and proper selection of anti-tubercular treatment (ATT) for drug resistance TB (DR-TB) is mandatory. It can be achieved with rapid molecular drug sensitivity testing and administering all oral shorter treatment regimens (SOTR) for drug-resistant TB patients.

Hasina Akhter¹, Syed Sakhawat Hussain² , Ahmed Parvez Zabeen³

¹Associate Professor, Department of Microbiology, Bangladesh Dental College, Dhaka, ²Professor Department of Biochemistry, Parkview Medical College, Sylhet, ³Dr. Ahmed Parvez Zabeen, Divisional Tuberculosis (TB) Expert, National Tuberculosis Control Program (NTP), Bangladesh

Parkview Medical Journal 

An official Journal of Parkview Medical College, Sylhet, Bnagladesh 

TB Global Leaders Visit Bangladesh

The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and STOP Partnership's senior team visited Bangladesh. Both Executive Directors visited together to support Bangladesh's goal to END TB by 2030. Bangladesh is the seventh high-burden country in the world for TB. Both drug-sensitive TB and drug-resistant TB are prevalent in Bangladesh.

Mr. Peter Sands and Ms. Lucica Ditiu with Honorable Prime Minister Sheikh Hasina at Gonobhaban

Mr. Peter Sands, ED, GFATM, and Dr. Ahmed Parvez Zabeen, Divisional TB Expert, Dhaka, NTP

Ms. Lucica Ditiu, ED, STOP TB Partnership, and Dr. Ahmed Parvez Zabeen, Divisional TB Expert, NTP, Bangladesh

GFATM Team 

The GFATM Team at Community Clinic (CC), Rupgang, Narayanganj

The GFATM Team at Mugda Medical College and Hospital, Dhaka 

Ms. Luciaca, ED, STOP TB Partnership, Dr. Ahmed Parvez Zabeen and Dr. Ayesha Akhter, Deputy Director, Shamoli TB Hospital, Dhaka    

During their visit, the Executive Directors of GFATM and STOP Partnership, Mr. Peter Sands and Ms. Lucica Ditiu, paid a courtesy call to Honorable Prime Minister Sheikh Hasina. They were impressed by the Prime Minister's comprehensive knowledge of Tuberculosis, AIDS, and Malaria. The Global Fund and Stop TB Partnership aim to involve Prime Minister Sheikh Hasina in their coalition of leaders as a champion of The Global Fund (GFATM). The list of coalition leaders includes Indian Prime Minister Narendra Modi and Brazilian President Luiz Inácio Lula da Silva, among others. These two organizations mainly focus on TB, HIV, and Malaria in Bangladesh and seek to strengthen their relationship with the country. The Executive Directors also expressed their desire for Prime Minister Sheikh Hasina to leverage her connections and networks with world leaders for funding to eliminate Tuberculosis, AIDS, and Malaria.

Subsequently, the GFATM and STOP TB Partnership Executive Directors and their team visited Tuberculosis Control activities at the community and facility levels.